Tvardi Therapeutics (TVRD) Total Liabilities (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Total Liabilities of $11.3 million for Q1 2026, up 1.66% sequentially from $11.1 million in Q4 2025, and down 75.94% YoY from $47.0 million in Q1 2025.
Tvardi Therapeutics (TVRD) Total Liabilities (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Total Liabilities for 14 years, with the latest figure at $11.3 million in Q1 2026.
- Quarterly Total Liabilities fell 75.94% year-over-year to $11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (down 75.94% YoY) and the FY2025 annual result came in at $11.1 million, down 72.75% from the prior year.
- Total Liabilities climbed to $11.3 million in Q1 2026 per TVRD's latest filing, from $11.1 million in the prior quarter.
- Over five years, Total Liabilities peaked at $226.6 million in Q2 2022 and troughed at $10.8 million in Q2 2025.
- A 5-year average of $86.1 million and a median of $60.3 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities plunged 90.5% in 2022, then surged 193.12% in 2023.
- Over 5 years, Total Liabilities stood at $23.5 million in 2022, then jumped by 193.12% to $68.8 million in 2023, then slumped by 40.62% to $40.8 million in 2024, then tumbled by 72.75% to $11.1 million in 2025, then rose by 1.66% to $11.3 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $11.3 million, $11.1 million, and $11.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | 9.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.31 Mn |
| Dec 31, 2025 | 11.13 Mn |
| Sep 30, 2025 | 11.16 Mn |
| Jun 30, 2025 | 10.82 Mn |
| Mar 31, 2025 | 47.02 Mn |
| Dec 31, 2024 | 40.83 Mn |
| Sep 30, 2024 | 50.62 Mn |
| Jun 30, 2024 | 60.90 Mn |
| Mar 31, 2024 | 60.30 Mn |
| Dec 31, 2023 | 68.76 Mn |
| Sep 30, 2023 | 115.34 Mn |
| Jun 30, 2023 | 134.39 Mn |
| Mar 31, 2023 | 153.28 Mn |
| Dec 31, 2022 | 23.46 Mn |
| Sep 30, 2022 | 213.51 Mn |
| Jun 30, 2022 | 226.57 Mn |
| Mar 31, 2022 | 223.87 Mn |
| Dec 31, 2021 | 247.06 Mn |
| Sep 30, 2021 | 225.09 Mn |
| Jun 30, 2021 | 221.45 Mn |